Berobenatide vs zovaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Berobenatide
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
Reported efficacy
Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)
Result source: NCT06712836
zovaglutide
Developed by Beijing QL Biopharmaceutical
NCT07020884 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial (n=303) in adults with overweight or obesity found that ZT002 produced significantly greater weight loss than placebo at 24 weeks across all doses tested, up to 14.4% versus 2.4% with placebo (p<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT07443059 (registry estimate)
Reported efficacy
The percentage change from baseline in weight after 24 weeks of treatment. (baseline, 24 weeks): Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001. (met)
Result source: NCT07020884
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Berobenatide | zovaglutide |
|---|---|---|
| Body weight, % change | —Trial running · NCT07311850 | -13.8% vs -2.4%a−11.4 vs placeboNCT070208843 other results
|
| Weight loss of 5% or more | —Trial running · NCT07311850 | —Trial running · NCT07230119 |
| Weight loss of 10% or more | —Trial running · NCT07311850 | —Trial running · NCT07230119 |
| Waist circumference, change (cm) | —Trial running · NCT07311850 | —Trial running · NCT07230119 |
Body weight, % change
- Berobenatide
- —Trial running · NCT07311850
- zovaglutide
- -13.8% vs -2.4%a−11.4 vs placeboNCT07020884
3 other results
- -14.4% vs -2.4% NCT07020884
- -10.6% vs -2.4% NCT07020884
- -12.5% vs -2.4% NCT07020884
Weight loss of 5% or more
- Berobenatide
- —Trial running · NCT07311850
- zovaglutide
- —Trial running · NCT07230119
Weight loss of 10% or more
- Berobenatide
- —Trial running · NCT07311850
- zovaglutide
- —Trial running · NCT07230119
Waist circumference, change (cm)
- Berobenatide
- —Trial running · NCT07311850
- zovaglutide
- —Trial running · NCT07230119
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
zovaglutide
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · zovaglutide's landscape